Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.73 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.61 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.59 |
| ▸ | PTGES | O14684 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27701819 | 0.85 | PGR (0.57) | PGRNR3C1MEN1KMT2AL3MBTL1 | |
| SCHEMBL6121647 | 0.85 | TAS2R14 (0.79) | PGRALDH1A1TAS2R14CNR1CNR2 | |
| SCHEMBL6122995 | 0.84 | PGR (0.57) | PGRNR3C1MEN1KMT2AL3MBTL1 | |
| SCHEMBL5330652 | 0.81 | ESR1 (0.78) | PGRNR3C1MEN1KMT2AL3MBTL1 | |
| SCHEMBL1098229 | 0.80 | PGR (0.53) | PGRNR3C1MEN1KMT2AL3MBTL1 | |
| SCHEMBL302104 | 0.79 | LMNA (0.61) | PGRMEN1KMT2ALMNAMAPT | |
| SCHEMBL7335030 | 0.79 | PGR (0.63) | PGRNR3C1MEN1KMT2AL3MBTL1 | |
| SCHEMBL7326459 | 0.78 | PGR (0.62) | PGRNR3C1MEN1KMT2ALMNA | |
| SCHEMBL1100782 | 0.78 | PGR (0.50) | PGRNR3C1L3MBTL1LMNAMAPT | |
| SCHEMBL2119407 | 0.77 | LMNA (0.78) | PGRNR3C1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640721-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2013-09-25 | — | — | EP | claimed |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2013-09-12 | — | — | US | claimed |
| WO-2012068251-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2012-05-24 | — | — | WO | claimed |
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | 7 HILLS PHARMA INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12201686-B2 | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | 7 HILLS PHARMA INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240189360-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA INC. (US) | 2024-06-13 | — | — | US | disclosed |
| US-11484524-B2 | Compositions and methods to improve adoptive cell therapies | 7 Hills Pharma LLC (US) | 2022-11-01 | — | — | US | disclosed |
| CN-107820429-B | Novel compositions and methods for immunotherapy comprising small molecule integrin receptor-ligand agonist adjuvants | 7山药物有限责任公司 | 2022-08-16 | — | — | CN | disclosed |
| US-11311619-B2 | Integrin activator vaccine compositions | 7 Hills Pharma Inc. and Texas Heart Institute (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3104867-B1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 Hills Pharma LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20220001009-A1 | NOVEL COMPOSITIONS INCLUDING A THERAPEUTIC ANTIBODIES AND/OR A CHECKPOINT INHIBITOR AND AN INTEGRIN ACTIVATING COMPOUND | 7 Hills Pharma LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-12-24 | — | — | US | disclosed |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-10-15 | — | — | US | disclosed |
| US-20150250883-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA INC. | 2015-09-10 | — | — | US | disclosed |
| WO-2015123447-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA, LLC (US) | 2015-08-20 | — | — | WO | disclosed |
| EP-2881393-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2881392-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2640721-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012068251-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311619-B2 | Integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA1 | PGR 2865/4885NR3C1 2977/4885MEN1 3351/4885 |
| US-11484524-B2 | Compositions and methods to improve adoptive cell therapies | ITGB7, ITGB1, ITGA1 | PGR 2797/4885NR3C1 1167/4885MEN1 2065/4885 |
| US-20220001009-A1 | NOVEL COMPOSITIONS INCLUDING A THERAPEUTIC ANTIBODIES AND/OR A CHECKPOINT INHIBITOR AND AN INTEGRIN ACTIVATING COMPOUND | CD47, ITGB1, ITGAM | PGR 2296/4885NR3C1 3312/4885MEN1 2463/4885 |
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | CD4, VCAM1, ITGA1 | PGR 2826/4885NR3C1 1826/4885MEN1 1041/4885 |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | PGR 2122/4885NR3C1 1011/4885MEN1 3676/4885 |
| US-20150250883-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | ITGB7, ITGB1, ITGA1 | PGR 2163/4885NR3C1 704/4885MEN1 2106/4885 |
| US-12201686-B2 | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | CD47, CD274, ITGB1 | PGR 1576/4885NR3C1 2989/4885MEN1 2026/4885 |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | PGR 2214/4885NR3C1 1078/4885MEN1 3845/4885 |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | PGR 2214/4885NR3C1 1078/4885MEN1 3845/4885 |
| US-20240189360-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | CXCL12, ITGB3, ITGB7 | PGR 1721/4885NR3C1 887/4885MEN1 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.